Home › Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA
 

Keywords :   


Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA

2016-06-01 06:09:24| drugdiscoveryonline Home Page

Cerulean Pharma Inc., a clinical-stage company developing nanoparticle-drug conjugates (NDCs), recently announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate, CRLX101, in combination with LYNPARZA (olaparib) in patients with advanced solid tumors

Tags: with trial combination phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.05ELF Beauty Teams with Billie Jean King to Change the Board Game to Support Inclusivity
05.05Target Faces Lawsuit Over Sunscreen Coral Bleaching Claims
05.05Goops Latest Launch & Hain Celestial Streamlines Portfolio
05.05The Summer of Sister Golden Hair
05.05Persil Laundry Detergent Rebrands
05.05Weekly Recap: Carefree Adds Pads to Lineup, Soft N Dry Secures Private Label Sales Network ...
05.05How Brexit is not 'done' for Northern Ireland
05.05Is Zimbabwe zigzagging into further currency chaos?
More »